CY1110464T1 - Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1 - Google Patents

Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1

Info

Publication number
CY1110464T1
CY1110464T1 CY20091100501T CY091100501T CY1110464T1 CY 1110464 T1 CY1110464 T1 CY 1110464T1 CY 20091100501 T CY20091100501 T CY 20091100501T CY 091100501 T CY091100501 T CY 091100501T CY 1110464 T1 CY1110464 T1 CY 1110464T1
Authority
CY
Cyprus
Prior art keywords
beta
adenergic
pyrazolopyridine
producers
cells
Prior art date
Application number
CY20091100501T
Other languages
Greek (el)
English (en)
Inventor
Henning Steinhagen
Jochen Huber
Kurt Ritter
Bernard Pirard
Kirsten Bjergarde
Marcel Patek
Martin Smrcina
Linli Wei
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1110464T1 publication Critical patent/CY1110464T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20091100501T 2005-06-27 2009-05-11 Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1 CY1110464T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05013774 2005-06-27
EP06754324A EP1899333B1 (en) 2005-06-27 2006-06-13 Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1

Publications (1)

Publication Number Publication Date
CY1110464T1 true CY1110464T1 (el) 2015-04-29

Family

ID=35395578

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100501T CY1110464T1 (el) 2005-06-27 2009-05-11 Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1

Country Status (30)

Country Link
US (1) US7910602B2 (https=)
EP (1) EP1899333B1 (https=)
JP (1) JP5010594B2 (https=)
KR (1) KR20080020638A (https=)
CN (1) CN101208340B (https=)
AR (1) AR054514A1 (https=)
AT (1) ATE423118T1 (https=)
AU (1) AU2006264044A1 (https=)
BR (1) BRPI0612320A2 (https=)
CA (1) CA2611296A1 (https=)
CY (1) CY1110464T1 (https=)
DE (1) DE602006005242D1 (https=)
DK (1) DK1899333T3 (https=)
ES (1) ES2322197T3 (https=)
HR (1) HRP20090244T2 (https=)
IL (1) IL188381A0 (https=)
MA (1) MA29498B1 (https=)
MX (1) MX2007015829A (https=)
MY (1) MY139016A (https=)
NO (1) NO20080392L (https=)
NZ (1) NZ564757A (https=)
PL (1) PL1899333T3 (https=)
PT (1) PT1899333E (https=)
RS (1) RS50821B (https=)
RU (1) RU2415855C2 (https=)
SI (1) SI1899333T1 (https=)
TW (1) TW200800982A (https=)
UY (1) UY29632A1 (https=)
WO (1) WO2007000241A1 (https=)
ZA (1) ZA200709853B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
US9321787B2 (en) * 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
GB201410815D0 (en) * 2014-06-17 2014-07-30 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
CN112955450A (zh) * 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
EP4041730A1 (en) 2019-10-01 2022-08-17 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2024137671A1 (en) * 2022-12-20 2024-06-27 Exelixis, Inc. Compounds that inhibit pkmyt1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034563A1 (en) * 1994-06-16 1995-12-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
ATE355841T1 (de) * 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
BR0313262A (pt) * 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체

Also Published As

Publication number Publication date
NZ564757A (en) 2009-12-24
DE602006005242D1 (de) 2009-04-02
UY29632A1 (es) 2007-01-31
PT1899333E (pt) 2009-04-23
MX2007015829A (es) 2008-02-22
RU2008102970A (ru) 2009-08-10
MY139016A (en) 2009-08-28
ATE423118T1 (de) 2009-03-15
CA2611296A1 (en) 2007-01-04
ES2322197T3 (es) 2009-06-17
CN101208340A (zh) 2008-06-25
JP5010594B2 (ja) 2012-08-29
TW200800982A (en) 2008-01-01
WO2007000241A1 (en) 2007-01-04
KR20080020638A (ko) 2008-03-05
NO20080392L (no) 2008-02-28
RU2415855C2 (ru) 2011-04-10
US20080227777A1 (en) 2008-09-18
RS50821B (sr) 2010-08-31
MA29498B1 (fr) 2008-05-02
EP1899333B1 (en) 2009-02-18
CN101208340B (zh) 2010-12-22
IL188381A0 (en) 2008-04-13
US7910602B2 (en) 2011-03-22
HRP20090244T2 (hr) 2009-07-31
EP1899333A1 (en) 2008-03-19
AR054514A1 (es) 2007-06-27
SI1899333T1 (sl) 2009-08-31
DK1899333T3 (da) 2009-06-15
ZA200709853B (en) 2008-12-31
JP2008543957A (ja) 2008-12-04
BRPI0612320A2 (pt) 2010-11-09
HRP20090244T1 (en) 2009-06-30
AU2006264044A1 (en) 2007-01-04
PL1899333T3 (pl) 2009-07-31

Similar Documents

Publication Publication Date Title
CY1110464T1 (el) Παραγωγα πυραζολοπυριδινης ως αναστολεις του βητα-αδρενεργικου υποδοχεα της κινασης1
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
CY1118498T1 (el) Παραγωγα πυριδαζινονης
CY1113617T1 (el) Νεα παραγωγα φαινυλαμινοπυριμιδινης ως αναστολεις της κινασης bcr-abl
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CY1118717T1 (el) Αναστολεις c-fms κινασης
LU93078I2 (fr) Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
EA200900184A1 (ru) 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
EA200901241A1 (ru) Соединения для лечения гепатита с
CY1115898T1 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
EA200900676A1 (ru) Ингибиторы вируса гепатита с
CY1113443T1 (el) Παραγωγα πυριδαζινονης
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
NO20073105L (no) Pyridazinonforbindelser
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
ATE554087T1 (de) Neue kinaseinhibitoren